Navigation Links
AMRI Awarded Development and Manufacture Contract from the UK Government
Date:9/30/2013

ALBANY, N.Y., Sept. 30, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that its wholly owned subsidiary, Albany Molecular Research (UK) Ltd., located in Holywell, Wales, United Kingdom, has been awarded a seven-year contract  for the development and manufacture of an active ingredient under clinical evaluation. The contract was awarded by the Defense Science and Technology Laboratory (Dstl), acting on behalf of the United Kingdom's Secretary of State for Defence, the Department of National Defence of Canada and Minister of Defence of the Kingdom of the Netherlands.

AMRI will initially work on the development and scale-up of the investigational drug, and subsequently the manufacture and supply for use during phase 1 clinical trials. If the trials are successful, AMRI will be in a strong position to become the commercial manufacturer of the product for distribution to the government partners of this contract including the United Kingdom, Netherlands and Canada.

"We are excited for the opportunity to work on this important project for the UK government," said AMRI's President and CEO, Thomas E. D'Ambra, Ph.D. "Government contracts and related collaborations outside of our typical outsourcing contracts with biotechnology and pharmaceutical companies are part of our strategy to diversify our revenue base while making our high-quality services available to all industries, sectors and organizations that can benefit from our strengths in discovery, development and manufacturing."

This collaboration underscores AMRI's expertise in providing SMARTSOURCING™ solutions to government agencies working to solve critical health issues. This includes work as both a contractor and subcontractor for various agencies of the U.S. government. AMRI has been a subcontractor in the manufacturing arena for the U.S. Department of Defense for more than a decade. In August 2011, AMRI received a federal contract award from the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network (BPN). This five-year contract provides AMRI with funding of up to $43 million, based on the number of approved projects and availability of funds.

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at http://www.amriglobal.com/ or follow us on Twitter (@amriglobal).

About Albany Molecular Research (UK) Ltd.
Albany Molecular Research (UK) Ltd., a wholly owned subsidiary of AMRI, provides development and manufacturing services, including pre-clinical and Phase I – III product development, as well as commercial manufacturing for approved products. The 14-acre site is located about 60 miles outside of Manchester, England and contains Kilo lab, pilot plant and large-scale manufacturing capabilities. In 2012, the site received a Good Manufacturing Practice (GMP) certificate from the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government for AMRI's manufacturing facility in Holywell, Wales, UK, underscoring the quality of the facility and its growth potential.


'/>"/>
SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Numotion Awarded Best Complex Rehab Provider
2. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
3. Access Pharmaceuticals Awarded Second European Patent for MuGard
4. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
5. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
6. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
7. Carolina Piedmont Capital Awarded VOSB Certification
8. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
9. Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
10. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
11. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Brady (NYSE:BRC), a global leader in industrial and ... B-7569 vinyl label materials received certification for the BS5609 British Marine Standard. This ... and legible, for use on chemical drums shipped by sea. , “Achieving ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA Agency ... (AOR) for Theravent, Inc. , the makers of a revolutionary new device ... Healthcare, is now working to expand distribution in anticipation of a national launch. ...
(Date:4/21/2017)... Dallas, TX (PRWEB) , ... April 21, 2017 ... ... Sleep Care products, announced an exciting new partnership with the highly regarded and ... of Airway Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and ...
(Date:4/21/2017)... Lake City, UT (PRWEB) , ... April 21, 2017 , ... ... staffing solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed ... way for the next chapter of growth for our agency and our ability to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... are five common elements between the Obamacare program that most Republicans love to ... uses Warfarin poison to kill hogs. , Like Obamacare, the Miller program ...
Breaking Medicine News(10 mins):